Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...
Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. The number of basic science papers published by recipients of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback